Select therapeutic use:
Indications for ANZEMET:
Prevention of nausea & vomiting associated with moderately emetogenic cancer chemotherapy, including initial and repeat courses.
≥16yrs: 100mg within 1hr before chemotherapy.
<2yrs: not established. 2–16yrs: Chemotherapy-induced: 1.8mg/kg (max 100mg) within 1hr before chemotherapy; or, may give IV soln and mix 1.8mg/kg (max 100mg) into apple or apple-grape juice and taken orally within 1hr before chemotherapy.
Inj soln administered by IV: Prevention of nausea & vomiting associated with emetogenic cancer chemotherapy, including initial and repeat courses in adults and children.
Increased risk of developing QTc, PR and QRS interval prolongation. Avoid in patients with congenital QT syndrome, hypokalemia, hypomagnesemia, complete heart block or risk of (unless paced). Correct electrolyte imbalances prior to therapy. Monitor ECG periodically. CHF. Bradycardia. Pre-existing conduction abnormalities and underlying structural heart disease. Sick sinus syndrome. Atrial fibrillation with slow ventricular response. Recent MI. Renal impairment. Elderly. Pregnancy (Cat.B). Nursing mothers.
Selective 5-HT3 receptor antagonist.
Caution with drugs which can prolong ECG intervals (eg, verapamil, flecainide, quinidine), diuretics, and with cumulative high-dose anthracycline therapy. Serotonin syndrome possible with concomitant serotonergic drugs (eg, SSRIs, SNRIs). Potentiated by cimetidine, atenolol (IV dolasetron). Antagonized by rifampin.
Headache, dizziness, pain, fatigue, diarrhea, bradycardia, tachycardia, dyspepsia, chills/shivers, ECG changes, 2nd or 3rd-degree AV block; serotonin syndrome (discontinue if occurs).
Tabs—5; Single-use vials (100mg/5mL)—1; Single-use vials (12.5mg/0.625mL)—6; Multidose vial (500mg/25mL)—1